Spyre Therapeutics, Inc. (SYRE) Earnings Call Transcripts
Spyre Therapeutics, Inc.'s Latest Earnings Call - April 13, 2026
In the first quarter of 2026, Spyre Therapeutics, Inc. reported significant progress in its SKYLINE trial for SPY001, an investigational treatment for ulcerative colitis. The company announced positive top-line results from Part A of the trial, indicating that SPY001 met its primary endpoint with a change from baseline in the Robarts Histopathology Index (RHI) of negative 9.2 (p < 0.0001). Management highlighted that 40% of participants achieved clinical remission and 51% showed endoscopic improvement, which positions SPY001 favorably against existing therapies. The company is optimistic about advancing to Part B of the trial, where it will explore combination therapies, and management signaled that they are confident in SPY001's potential as a best-in-class treatment, which could significantly impact the stock moving forward.
Reported metrics
| Metric | Value |
|---|---|
| Change from Baseline in RHI | -9.2 (positive) |
| Clinical Remission Rate | 40% (positive) |
| Endoscopic Improvement Rate | 51% (positive) |
| Participant Enrollment | 130 (positive) |
| Adverse Events | few treatment-emergent adverse events (positive) |
| Market Size for IBD | $25 billion (positive) |
Guidance from management
Management indicated confidence in SPY001's potential as a monotherapy and in combination therapies, stating that they are likely to advance multiple products into pivotal development based on the positive results from Part A.
What management said
Good question. Maybe I'll take the last one first, which is that we haven't said exactly what we're dosing here, but that initial dose that we're providing is kind of a multiple of where vedolizumab starts with that initial IV dose. And so I think we are getting quite a bit of drug on board right away within a lower dose at a later IV. And so I think that may be what's driving that fast efficacy in terms of getting e...
Sure. So Part A, patients were not tapering during the induction period. But for Part B, we will have a paper starting at week 6 just like the VEGA study since we will have combinations in Part B, and we want to minimize the time when a patient may be on triple immunosuppression. So in Part B, by week 12, patients should be off steroids and therefore, that should help with the placebo response rate. In terms of the P...
What analysts pressed on
Analysts raised questions about the need for head-to-head studies against existing therapies and the consistency of efficacy across different geographic regions. Concerns were also noted regarding the potential impact of treatment-experienced patients on overall efficacy.
Main topics on the call
- Positive Trial Results — SPY001 demonstrated a change from baseline in RHI of negative 9.2 with a p-value of less than 0.0001, indicating strong efficacy. Management stated, "we believe SPY001 is one of the most promising single agents in develo...
- High Efficacy Rates — The trial reported that 40% of participants achieved clinical remission and 51% achieved endoscopic improvement, which are among the highest rates observed in precedent trials. Management noted, "our 51% endoscopic impro...
- Safety Profile — SPY001 was well tolerated with few treatment-emergent adverse events, aligning with the safety profile of the anti-alpha-4 beta-7 class. Management emphasized, "the benign nature of this profile appears consistent with t...
- Transition to Part B of the Trial — The company is transitioning to Part B of the SKYLINE study, which will include placebo-controlled evaluations and combination therapies. Management expressed confidence, stating, "we believe enthusiasm will only increas...
Read the full Spyre Therapeutics, Inc. transcript (April 13, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (SYRE) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 18 calls on record spanning January 15, 2020 to September 9, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 18 Spyre Therapeutics, Inc. earnings call transcripts on record, spanning January 15, 2020 to September 9, 2026. Based on this history, Spyre Therapeutics, Inc. reports semi-annually. The most recent call on file is dated September 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- SYRE
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 18
- First call
- January 15, 2020
- Most recent
- September 9, 2026
- Reporting cadence
- semi-annually